Mounjaro+Zepbound Script Tracker

研报英文原文证据摘录

Mounjaro+Zepbound Script Tracker

UpdateM

Diabesity Catalyst Calender

Exhibit 44: MS Diabesity Catalyst Calendar

Company Timing Drug Comparator(s) Event

AMGN 4Q25 MariTide (AMG 133) Placebo Data from part 2 of Ph2 study (incl. quarterly dosing)

GPCR YE25 ACCG-2671 - Advance DACRA into clinic

NVO 1Q26 CagriSema Cagri/Sema/Tirzepatide Ph3 CagriSema vs. Zepbound in obesity H2H data (REDEFINE-4)

LLY 1Q26 Orforglipron (Oral GLP1) Insulin Glargine Ph3 CV risk non-inferiority study in patients with T2D + Obesity and increased CV Risk (ACHIEVE-4)

NVO 2H25-1H26 CagriSema Cagri/Sema/Placebo Ph3 T2D data (4 studies, REIMAGINE 1 -4)

NVO 2025/26 CagriSema Cagri/Sema/Placebo Ph2 data in patients with T2D + CKD

LLY 2025-2026 Orforglipron (Oral GLP1) - FDA filing in diabetes/obesity

ZEAL 2025/26 Survodutide (GLP1/GCGR) Placebo Ph3 in obesity -T2D (SYNCHRONIZE-1) data

ZEAL 2025/26 Survodutide (GLP1/GCGR) Placebo Ph3 in obesity +T2D (SYNCHRONIZE-2) data

VKTX May 12-15, 2026 Oral VK2735 Placebo Present full Ph2 data from VENTURE-Oral trial at European Congress on Obesity

ROG 1H26 CT-868 Placebo Ph2 data in T1D with obesity at medical conference

ZEAL 2026 Survodutide (GLP1/GCGR) Placebo Ph3 CV safety study in obese/overweight (SYNCHRONIZE-CVOT) data

ZEAL 2026 Petrelintide (LA amylin) - Initiate Ph3 monotherapy studies in obesity/T2D

NVO 2026 CagriSema Cagri/Sema/Tirzepatide REIMAGINE 5 Ph3 data - 1mg Cagri vs. 5mg Tirzepatide

ROG 2026 CT-388 Placebo Disclose Ph2 final data in obese/overweight pts

LLY 2026 High Dose Tirzepatide Placebo Ph2 data exploring higher doses of tirzepatide in patients with T2D + obesity

LLY 2026 Orforglipron Placebo Ph3 ATTAIN-MAINTAIN trial of orfor as maintenance therapy in obese patients

LLY 2026 Orforglipron Placebo Ph3 study in obesity+OSA (ATTAIN-OSA)